<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850081</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM2407</org_study_id>
    <nct_id>NCT02850081</nct_id>
  </id_info>
  <brief_title>Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes</brief_title>
  <acronym>STANCE</acronym>
  <official_title>Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that pre-operative statin use is neuroprotective at maximal&#xD;
      doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin&#xD;
      doses for two weeks (12-18 days) prior to CEA using change in performance on a battery&#xD;
      neuropsychometric tests as outcome measure. Study will recruit patients based on their&#xD;
      preexisting statin regimen.&#xD;
&#xD;
      The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use&#xD;
      is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early&#xD;
      mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against&#xD;
      eCD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carotid endarterectomy (CEA) is a common surgery performed to reduce the risk of stroke in&#xD;
      patients with carotid artery narrowing. Statins, a class of drugs usually used to lower blood&#xD;
      cholesterol, may protect the brain after surgery. Specific statins have been shown to protect&#xD;
      the brain after surgery when compared to others. eCD affects about 25% of patients undergoing&#xD;
      CEA and about 15% of undergoing asymptomatic CEA. It is associated with marked elevations in&#xD;
      tissue markers of cerebral injury and is associated with earlier post-CEA mortality. This&#xD;
      clinically significant, but subtle, cerebral injury is 10 times more common than stroke and&#xD;
      its mechanism appears to be similarly related to regional hypoperfusion and ischemia. It is&#xD;
      imperative to determine in a prospective randomized trial whether alteration/increase of&#xD;
      preoperative statin regimens leads to improved neurologic outcome and an even lower incidence&#xD;
      of stroke and possibly greater survival.&#xD;
&#xD;
      In order to optimally design and conduct such a trial it is critical to: 1) explore the&#xD;
      safety and feasibility of altering statin regimen acutely (approximately 2 weeks) before CEA,&#xD;
      and 2) clearly establish the neuroprotective outcome of an acute alteration in statin&#xD;
      regimen. This would promote a better understanding of statin neuroprotection in humans and&#xD;
      determine the statin treatment that affords the most neuroprotection in patients undergoing&#xD;
      one of the most commonly performed procedures in the US.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of eCD</measure>
    <time_frame>30 Days: 1) Pre-op vs. Post-CEA Day 1 (12-25 hrs post-op) and 2) Pre-op vs. Post-CEA Day 30</time_frame>
    <description>Neurocognitive assessments ≥2SD worse than reference group in two or more cognitive domains or (b) ≥1.5SD worse than the reference group in all cognitive domains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of early mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Data will be collected by follow up phone call</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <condition>Strokes</condition>
  <arm_group>
    <arm_group_label>Observational - Maximal Dose - ARM 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Less Than Maximal Dose - ARM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin &lt;40mg without amlodipine and &lt;20mg with amlodipine; Atorvastatin (&lt;80mg) or Rosuvastatin (&lt;20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin Naive - ARM 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Standard of care treatment (one of four):&#xD;
Simvastatin (to 40mg without amlodipine)&#xD;
Simvastatin (to 20 mg if currently on amlodipine)&#xD;
Atorvastatin (to 80mg)&#xD;
Rosuvastatin (to 20mg)</description>
    <arm_group_label>Less Than Maximal Dose - ARM 2</arm_group_label>
    <other_name>Pre-existing statin regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>A lipid-lowering agent and for prevention of events associated with cardiovascular disease.&#xD;
10 mg or 80 mg capsules</description>
    <arm_group_label>Statin Naive - ARM 3</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.</description>
    <arm_group_label>Less Than Maximal Dose - ARM 2</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years of age.&#xD;
&#xD;
          2. Patient is currently on atorvastatin or simvastatin or rosuvastatin or statin naïve&#xD;
             (no statins in the last 30 days).&#xD;
&#xD;
          3. The patient has unilateral or bilateral carotid artery stenosis that is considered&#xD;
             severe (carotid artery diameter reduction ≥ 70%) as defined by:&#xD;
&#xD;
               1. Peak systolic velocity of at least 230 cm/s plus at least one of these:&#xD;
&#xD;
               2. End diastolic velocity ≥ 100 cm/s OR&#xD;
&#xD;
               3. CTA showing ≥ 70% stenosis OR&#xD;
&#xD;
               4. MRA showing ≥ 70% stenosis&#xD;
&#xD;
          4. This stenosis has not caused any stroke, transient cerebral ischemia, or other&#xD;
             relevant neurological symptoms in the past.&#xD;
&#xD;
          5. The patient's attending doctor(s) (PMD, cardiologist, vascular/neurosurgeon) AND the&#xD;
             patient have decided to proceed with a CEA to treat the patient's severe carotid&#xD;
             stenosis.&#xD;
&#xD;
          6. The patient has no known circumstance or condition likely to preclude 1 year follow-up&#xD;
             or adherence to the study protocol.&#xD;
&#xD;
          7. The patient is independent in their Activities of Daily Living at baseline.&#xD;
&#xD;
          8. Patient has the ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has underlying disease other than atherosclerosis (i.e. autoimmune disease,&#xD;
             known active malignancy).&#xD;
&#xD;
          2. Patient has documented dementia or screens out based on abnormal Baseline MoCA (≤25)&#xD;
             and AD8 (≥2).&#xD;
&#xD;
          3. Patient's life expectancy is &lt; 12 months.&#xD;
&#xD;
          4. Patient has advanced renal failure (serum creatinine &gt; 2.5 mg/dL)&#xD;
&#xD;
          5. Patient has evidence of severe congestive heart failure or has history of end-stage&#xD;
             cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina).&#xD;
&#xD;
          6. Patient has history of intolerance or allergic reaction to any statins (myotoxicity,&#xD;
             hepatic dysfunction, rash, etc.)&#xD;
&#xD;
          7. Patient has received an investigational drug within 30 days.&#xD;
&#xD;
          8. Patient is pregnant or lactating.&#xD;
&#xD;
          9. Patient is currently taking any of the following which have been shown to interact&#xD;
             with atorvastatin and/or simvastatin and/or rosuvastatin (as per current drug package&#xD;
             inserts):&#xD;
&#xD;
               -  Cyclosporine;&#xD;
&#xD;
               -  HIV Protease Inhibitors/Antivirals (e.g. rotanavir or plus rotanavir, tipranavir,&#xD;
                  lopinavir, boceprevir, saquinovir, darunavir, fosamprenavir, nelfinavir,&#xD;
                  efavirenz/tenofobir, atazanavir, simeprevir);&#xD;
&#xD;
               -  Hep C Protease Inhibitor/Antivirals (e.g. telapravir);&#xD;
&#xD;
               -  Antibiotics (i.e. cobicistat-containing products like Tybost,&#xD;
                  rifampin/rifampicin, clarithromycin, telithromycin, erythromycin);&#xD;
&#xD;
               -  Anti-fungals (i.e. itraconazole, ketoconazole, posaconazole, voriconazole,&#xD;
                  fluconazole); *Gemfibrozil; Other Fenofibrates (e.g. Tricor, fibric acid);&#xD;
&#xD;
               -  Niacin &gt; 1g/day or statins in combination with niacin (e.g. Vytorin, Simcor);&#xD;
&#xD;
               -  Colchicine;&#xD;
&#xD;
               -  Danazol;&#xD;
&#xD;
               -  Calcium Channel Blockers: Diltiazem, Varapamil;&#xD;
&#xD;
               -  Dronedarone;&#xD;
&#xD;
               -  Amiodarone;&#xD;
&#xD;
               -  Digoxin;&#xD;
&#xD;
               -  Ranolazine;&#xD;
&#xD;
               -  Nefazodone;&#xD;
&#xD;
               -  Warfarin/Coumadin;&#xD;
&#xD;
               -  Lomitapide;&#xD;
&#xD;
               -  Grapefruit juice &gt; 1.2 liters/day (40.5 ounces/day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward S Connolly, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center/New York Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Heyer, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebeca Aragon Garcia, BS</last_name>
    <phone>212-305-4679</phone>
    <email>ra2356@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josephine U Pucci, BA</last_name>
    <phone>2123054679</phone>
    <email>jup2102@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avery Freed</last_name>
      <phone>201-389-0194</phone>
      <email>afreed@valleyhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Sayles</last_name>
      <email>KSAYLES@valleyhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dorothea Altschul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College/The Vascular Group at Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208-3479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Kaim</last_name>
      <email>KaimR@mail.amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Sheehan</last_name>
      <email>SheehaA@mail.amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Courtney Warner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph C Darling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260-7016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Gay</last_name>
      <phone>716-440-4231</phone>
      <email>jgay@ubns.com</email>
    </contact>
    <contact_backup>
      <last_name>Reagan O'Toole</last_name>
      <email>rotoole@ubns.com</email>
    </contact_backup>
    <investigator>
      <last_name>Adnan Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Bott</last_name>
      <phone>212-263-2268</phone>
      <email>jacqueline.bott@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Apruzzese</last_name>
      <phone>212-241-8349</phone>
      <email>rebecca.apruzzese@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Milerva Santos</last_name>
      <email>milerva.santos@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>J Mocco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilia Bagiella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Aragon Garcia, BS</last_name>
      <phone>212-305-4679</phone>
      <email>ra2356@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Josephine U Pucci, BA</last_name>
      <phone>21123054679</phone>
      <email>jup2102@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Edward S Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise A Caccappolo Van Vliet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaakov Stern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Buchsbaum</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric J Heyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin L Heinzen-Cox, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University Medical College (Weill)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-4805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruchita Mehta</last_name>
      <email>rum2006@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>E. Sander Connolly</investigator_full_name>
    <investigator_title>Bennett M. Stein Professor of Neurological Surgery, Dept of Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>Carotid endarterectomy</keyword>
  <keyword>CEA</keyword>
  <keyword>stroke</keyword>
  <keyword>asymptomatic stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

